News & Press - Otsuka US
Oct 24, 2024 · Otsuka America Pharmaceutical, Inc. Phone: 609-249-7262. Email: [email protected]. Featured News. Press Release. New Report Reveals U.S. Family Caregivers Perform Equivalent of a Staggering $873.5 Billion Worth of Labor, Would Surpass Revenue of Top Global Companies.
News Releases | Otsuka Pharmaceutical Co., Ltd.
Oct 22, 2024 · Pharmaceuticals. Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn™, the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms.
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a …
3 days ago · ICU Medical, Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), global IV solutions ...
Otsuka Announces Positive Interim Results from the Phase 3 Trial …
Oct 22, 2024 · Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. today announce positive topline interim data from the ongoing Phase 3 clinical trial of sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgA nephropathy) in adults.
Otsuka, ICU Medical form joint venture to boost IV solution …
14 hours ago · Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of a new partner in ICU Medical. The two companies will join forces to ...
Otsuka Pharmaceutical Factory and ICU Medical Announce the ...
2 days ago · This is the news release page that Otsuka Pharmaceutical Factory sends. Information in the news releases is current as of the date of the news announcement. Otsuka Pharmaceutical Factory is a global company that aims to be the best partner for patients and healthcare professionals in the clinical nutrition field and continues to take on the challenge of …
Otsuka Pharmaceutical Announces Positive Topline Results from …
Oct 27, 2023 · Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity ...
ICU Medical, Otsuka Pharmaceutical Factory form joint venture
3 days ago · Nov. 12, 2024, 03:33 PM. ICU Medical (ICUI) and Otsuka Pharmaceutical Factory, global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint ...
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires ...
Dec 1, 2023 · On November 30 (U.S. time), Pharmavite LLC, a California-based subsidiary of Otsuka Pharmaceutical Co., Ltd., announced the acquisition of Bonafide Health, LLC, a company specializing in the creation and sale of products for women's health. Bonafide Health is based in the state of New York.
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating …
Mar 21, 2024 · PRINCETON, N.J. & TOKYO, March 21, 2024--Otsuka Pharmaceutical Development & Commercialization, Inc., and our parent company Otsuka Pharmaceutical, Co. Ltd., announce that interim data from...